
Sign up to save your podcasts
Or


Traditionally, we think of Parkinson's as a movement disorder—defined by slowed movement, stiff muscles, and involuntary shaking. But it turns out there are other symptoms that appear years or even decades before movement problems bring patients to the clinic: sleep disturbances, chronic constipation, and loss of smell.
For today's guest, these early symptoms represent an incredible opportunity to understand where Parkinson's begins and to identify patients much earlier in the disease.
Kathleen Poston is a neurologist and division chief for movement disorders at Stanford Medicine. She's also a member of the steering committee for the Knight Initiative for Brain Resilience at Wu Tsai Neuro, and advises the Michael J. Fox Foundation and pharmaceutical companies on Parkinson's research.
We discuss why non-motor symptoms might hold the key to early diagnosis, how new biomarkers are redefining the disease, and whether Parkinson's might actually start in the gut.
Learn More
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
We want to hear from your neurons! Email us at at [email protected]
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.
By Wu Tsai Neurosciences Institute at Stanford University, Nicholas Weiler5
2828 ratings
Traditionally, we think of Parkinson's as a movement disorder—defined by slowed movement, stiff muscles, and involuntary shaking. But it turns out there are other symptoms that appear years or even decades before movement problems bring patients to the clinic: sleep disturbances, chronic constipation, and loss of smell.
For today's guest, these early symptoms represent an incredible opportunity to understand where Parkinson's begins and to identify patients much earlier in the disease.
Kathleen Poston is a neurologist and division chief for movement disorders at Stanford Medicine. She's also a member of the steering committee for the Knight Initiative for Brain Resilience at Wu Tsai Neuro, and advises the Michael J. Fox Foundation and pharmaceutical companies on Parkinson's research.
We discuss why non-motor symptoms might hold the key to early diagnosis, how new biomarkers are redefining the disease, and whether Parkinson's might actually start in the gut.
Learn More
Send us a text!
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
We want to hear from your neurons! Email us at at [email protected]
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

91,297 Listeners

21,954 Listeners

43,837 Listeners

32,246 Listeners

38,430 Listeners

43,687 Listeners

26,242 Listeners

12,130 Listeners

6,467 Listeners

113,121 Listeners

7,244 Listeners

5,576 Listeners

16,525 Listeners

1,204 Listeners

749 Listeners